• 12 min read
• Published on 20 August 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 19 August 2026
Read article
The Phase Shift. Merck and Moderna just proved their personalised treatment could actually tackle melanoma. For mRNA cancer vaccine Nigerian investors tracking the data, this late-stage clinical success is a wake-up call. The science isn't just a pandemic tool anymore.
The Oncology Pivot. Smart capital is aggressively pricing in a future where these treatments become a broad platform for solid tumours. The Merck Moderna melanoma vaccine Nigeria and global markets are watching might completely redefine long-term pharmaceutical revenues. Execution is everything. Period.
The Access Play. Wondering how to buy MRNA stock from Nigeria without massive upfront capital? You don't need a fortune. Regulated platforms now let any mRNA vaccine stocks Lagos investor build a diversified portfolio with fractional shares and AI-driven insights. It's commission-free and built for beginners.
The Volatility Trap. Mixing biotech stocks Nigeria naira conversion costs and unpredictable FDA decisions is a brutal cocktail. A Moderna stock Nigerian retail investor must remember that clinical trials can fail. Complex pipelines mean you could lose money fast if the science stumbles.
I have spent enough time watching the markets to know a pharmaceutical fad when I see one. A few years ago, we were all armchair epidemiologists. We learned what mRNA meant, we watched biotech valuations defy gravity, and we assumed infectious diseases would be the perpetual golden goose. Then, inevitably, the world went back to normal. The pandemic premium evaporated, and the market asked the mRNA pioneers a very cynical, very necessary question.
What else have you got?
Well, Merck and Moderna have finally provided an answer, and it might just be the most consequential clinical trial result in the short history of mRNA outside of Covid. Their jointly developed, personalised cancer vaccine recently showed a meaningful benefit in reducing melanoma recurrence when added to Keytruda, which is Merck's blockbuster immunotherapy drug.
For those of you tracking this corner of biotech from Lagos, Abuja, or anywhere else, the implications are absolutely worth examining. But we must do so carefully, pragmatically, and entirely without the usual market hysteria.
The headline result from the Phase 3 trial was straightforward but undeniably significant. The combination of Moderna's personalised mRNA vaccine with Merck's Keytruda reduced the risk of melanoma recurrence or death when compared with Keytruda alone. I want to be clear here. This is not a preliminary signal from a tiny, early-stage study run out of a university basement. Phase 3 is the final, brutal, and most rigorous stage of clinical testing before a drug can even be considered for regulatory approval.
The vaccine itself works differently from almost anything that came before it. Moderna's technology reads the genetic mutations unique to a patient's specific tumour. The company then manufactures a bespoke mRNA sequence, much like a tailor cutting a suit on Savile Row, designed specifically to instruct that patient's immune system to recognise and attack those precise cancer cells. Each vaccine is built for one single person.
The mRNA molecule carries a temporary instruction to the body, triggers the immune response, and then quietly degrades. It is the molecular equivalent of a burner phone. More importantly, it does not alter your DNA.
Until now, mRNA's biggest commercial successes had been squarely in the realm of infectious disease. The fact that the platform has now demonstrated Phase 3 efficacy against a solid tumour changes the conversation entirely. If you are looking at the broader picture, you might want to explore the mRNA Vaccines: Could Non-COVID Markets Drive Growth? theme. The technology is beginning to look like a broad oncology platform, and to me, that is a materially different investment proposition.
Markets absorbed this news with exactly the kind of enthusiasm you would expect for a late-stage oncology readout. Moderna shares reacted notably on the announcement. Investors recognise that achieving positive Phase 3 data in the cancer space is a far harder mountain to climb than rolling out a seasonal Covid booster. For Merck, the result reinforces the long-term durability of its Keytruda franchise. Keytruda is already one of the best-selling drugs on the planet, and finding a new combination partner that could extend its clinical utility is commercially massive.
Success in Phase 3 does not equal guaranteed money.
Let us isolate that point, because it is crucial. Late-stage success matters because it compresses the timeline to commercialisation, but it is never a sure thing. Phase 3 success is simply the prerequisite for filing with regulatory bodies such as the FDA. The closer a drug gets to approval, the closer a company gets to generating actual revenue from it. That shift in probability is what tends to drive a stock's valuation.
The pipeline implications beyond melanoma are what the serious money is watching now. If personalised mRNA vaccines work in melanoma, the scientific rationale exists to test them in other tumour types with high mutational burdens. Lung cancer, bladder cancer, and certain gastrointestinal cancers could all be candidates for future programmes. None of this is guaranteed, and each new indication will require its own gruelling clinical trials. But the platform has passed its most important proof-of-concept test in oncology, which matters deeply for how analysts model the long-term value of both companies.
Here is where our conversation needs to be grounded in cold, hard reality. For an investor based in Nigeria, buying into American biotech is not simply a decision about which science looks interesting. It is a complex decision about dollar exposure, naira conversion costs, and the frankly terrifying volatility profile of clinical-stage equities.
The naira has faced sustained pressure against the dollar over recent years. As an investor, that cuts both ways. It means that holding dollar assets has, at times, provided a buffer as the naira value of those positions rose, even when the underlying US stock remained flat. However, it also means that the sheer cost of converting naira to dollars to make your initial investment has become an increasingly significant hurdle. Timing that conversion poorly can eat your returns before you have even clicked the buy button.
Then there is the biotech sector itself.
Clinical trial results can move biotech stocks by enormous percentages in a single afternoon. The Phase 3 success for this cancer vaccine was an undeniable win. Yet, the exact same mechanism that drives a stock sharply higher on positive data can drive it into the ground if a subsequent trial fails, if the FDA raises unexpected safety questions, or if a competitor simply produces a better drug. If you are considering positions in this sector, you must be under no illusion. You are not buying stable, dividend-generating utilities. You are buying innovation-driven companies operating in a space where brutal, binary outcomes are the norm.
Balancing this kind of exposure within a broader dollar portfolio is not just a sensible idea. It is a requirement for survival. A position in a massive pharmaceutical conglomerate like Merck carries a fundamentally different risk profile from a position in Moderna. Merck has multiple revenue streams and a diversified global business. Moderna remains heavily dependent on the future commercial success of its mRNA pipeline. Both companies could be appropriate for different portfolios, but neither should ever constitute the entirety of your dollar allocation.
Thankfully, Nigerian investors now have far more options for accessing US-listed stocks than they did a decade ago. Regulated platforms offering dollar-denominated accounts have finally democratised access. Nemo, which is regulated by the ADGM FSRA in Abu Dhabi under licence FSPN 200015, offers commission-free trading in US stocks including both of the companies we have discussed. Your accounts are protected by SIPC up to $500,000.
Perhaps most importantly, they offer fractional shares. You can build a position from as little as $1. To me, this is not just a marketing gimmick, it is a highly practical advantage when you are trying to size your way into volatile biotech names without betting the house.
Naira conversion is a practical step you must manage carefully. You have to convert your local currency to dollars before funding a brokerage account. The exchange rate you achieve, and the hidden fees applied by your bank or transfer service, will directly impact your entry price. You should compare providers ruthlessly.
Position sizing is something you must think through before placing a trade, not after you watch a stock gap down at the market open. The golden rule among seasoned biotech investors is to limit any single speculative position to a very small percentage of your total portfolio. Upside in this sector can be substantial, but the drawdowns can be equally severe. You can use Nemo's AI-powered research tools to assess analyst sentiment before making a move, but remember, all investments carry risk and you may lose money.
What exactly did the Merck and Moderna Phase 3 trial show? The trial demonstrated that combining Moderna's bespoke mRNA cancer vaccine with Merck's existing Keytruda drug reduced the risk of melanoma recurrence or death when compared to using Keytruda on its own. Because this was a Phase 3 result, it carries weight. It is the final stage of clinical testing.
Is this the first time mRNA technology has been used against cancer? It is the first time a personalised mRNA cancer vaccine has demonstrated positive results in a late-stage Phase 3 trial. Earlier studies showed promise, but Phase 3 is a materially higher hurdle. It is the standard required before knocking on the regulator's door.
Does this success mean the vaccine will definitely be approved? Absolutely not. Phase 3 success is necessary, but it is never sufficient on its own. The companies must now submit mountains of data to regulators like the FDA, who will conduct their own ruthless reviews. Timelines are long, and approvals are never guaranteed.
Can I actually buy these stocks from Nigeria? Yes, you can. Dollar-denominated brokerage platforms, including Nemo, provide direct access to US-listed equities. You will just need to fund your account in dollars, which requires navigating the naira conversion first.
How much capital do I need to start? With fractional shares on platforms like Nemo, you can start with a single dollar. This is incredibly useful for taking a small, exploratory position in expensive US stocks without committing vast sums of capital.
Are biotech stocks riskier than standard equities? Yes, quite frankly, they are. Their valuations are tied entirely to clinical trial outcomes and the whims of regulatory bodies. Positive news can drive sharp gains, but clinical failures can wipe out value overnight. All investments carry risk, and you must be prepared for the possibility of losing money.
What is the real difference between these two companies? Moderna is a biotechnology firm whose future depends heavily on its mRNA pipeline, encompassing Covid vaccines and these new oncology candidates. Merck is an established, diversified pharmaceutical giant with a vast portfolio of approved drugs. They carry completely different risk profiles. I am not a licensed advisor, and nothing here constitutes financial advice to buy or sell either security. Ensure you understand what you are buying before you write the cheque.
View the full Basket:mRNA Vaccines: Could Non-COVID Markets Drive Growth?
View the full Basket:mRNA Vaccines: Could Non-COVID Markets Drive Growth?
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 20 August 2026
Read article
Published on 19 August 2026
Read article